Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Eric J Lenze

10 papers in the library · 881 citations · publishing 2018-2026

Papers

Better Biomarkers, Faster Drugs, Stronger Models: Progress Towards Precision Psychiatry.

Missouri medicine January 1, 2023 Joshua S. Siegel, Craig S Pearson, Eric J Lenze 592 citations

New treatments for major depressive disorder are moving beyond traditional monoamine-targeting antidepressants toward options like κ-opioid antagonists, ketamine, and neurosteroids. These advances, combined with smartphone-based experience sampling and brain imaging, enable more precise diagnosis and symptom-specific measurement. This convergence heralds 'precision psychiatry'—selecting optimal treatments for individual patients. Anhedonia exemplifies this shift, evolving from a mere depression criterion to a transdiagnostic condition understood neurobiologically and targeted by novel pharmacotherapies. Functional testing of reward circuits in developing κ-opioid antagonists for anhedonia illustrates how other treatments, including psychedelics, may fit into future precision psychiatric care.

Psilocybin desynchronizes the human brain.

Nature August 1, 2024 Joshua S. Siegel, Subha Subramanian, Demetrius Perry et al. 241 citations

A single high dose of psilocybin (25 mg) massively disrupts functional connectivity in the human brain, causing more than threefold greater change than methylphenidate (40 mg). These changes are driven by desynchronization across spatial scales, dissolving network distinctions by reducing correlations within and anticorrelations between networks. The strongest effects occur in the default mode network, which is connected to the anterior hippocampus and is thought to create the sense of space, time, and self. Individual differences in connectivity changes are strongly linked to the subjective psychedelic experience. A persistent decrease in connectivity between the anterior hippocampus and default mode network lasts for weeks, suggesting a neuroanatomical correlate of the therapeutic and proplasticity effects of psychedelics.

Cognitive and Neurophysiological Recovery Following Electroconvulsive Therapy: A Study Protocol

Frontiers in Psychiatry May 14, 2018 Ben J Palanca, Hannah R. Maybrier, Angela M. Mickle et al. 16 citations

Electroconvulsive therapy (ECT) deliberately induces generalized seizures to treat severe psychiatric illness, offering a chance to study how consciousness, cognition, and brain activity recover after seizures. Fifteen patients with treatment-resistant major depressive disorder will receive right unilateral ECT under etomidate anesthesia. They will then undergo three treatments in randomized order: etomidate plus ECT, ketamine plus ECT, and ketamine plus sham ECT, repeated for six total sessions. Cognitive tests assess sensorimotor speed, working memory, and executive function before and after each treatment. The study will measure time to return of responsiveness, cognitive recovery trajectories, postictal delirium, and EEG changes. It aims to develop biomarkers for tailoring cognitive and emotional recovery in ECT patients.

Psilocybin desynchronizes brain networks

medRxiv August 24, 2023 Subha Subramanian, Demetrius Perry, Caterina Gratton et al. 14 citations preprint

Psilocybin disrupts connectivity across cortical networks and subcortical structures, producing more than three-fold greater acute changes in functional networks than methylphenidate. These changes are driven by desynchronization of brain activity across spatial scales, strongest in the default mode network (DMN), which is connected to the anterior hippocampus and thought to create our sense of self. Performing a perceptual task reduces psilocybin-induced network changes, suggesting a neurobiological basis for grounding during psychedelic therapy. Psilocybin induces a persistent decrease in functional connectivity between the anterior hippocampus and cortex (and DMN in particular), lasting for weeks but normalizing after six months. This persistent suppression of hippocampal-DMN connectivity represents a candidate neuroanatomical and mechanistic correlate for psilocybin's pro-plasticity and anti-depressant effects.

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.

American Journal of Psychotherapy May 6, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 7 citations

Practitioners of psychedelic therapy largely view physical touch as an important component of treatment, but they also emphasize strict professional boundaries and the necessity of patient consent. In a survey of 40 practitioners who had overseen an average of 41.4 psychedelic sessions, 70% agreed that therapeutic touch is crucial. However, most deemed specific forms of touch inappropriate: 63% considered bodywork inappropriate, and 98% considered full-body contact inappropriate. Free-response analysis showed 96% supported touching the patient's hand and 58% supported touching the shoulder. Unprompted, 63% of respondents stressed the importance of consent. These views may inform future practice.

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial

Scientific Data June 5, 2025 Subha Subramanian, Travis Rick Renau, Demetrius Perry et al. 4 citations

A psychedelic drug, psilocybin, and a comparison drug, methylphenidate, produce distinct acute and persistent changes in brain networks measurable with precision functional mapping, a technique that improves signal detection by repeatedly scanning individuals. Seven healthy adults underwent extensive baseline brain imaging, imaging shortly after drug intake, and follow-up scans for up to two weeks. Four participants repeated the psilocybin protocol months later. The dataset includes resting-state and task-based functional MRI, structural scans, and subjective experience reports. The authors release this resource to help researchers study how psilocybin and methylphenidate alter brain network organization over time.

Shrinking the know-do gap in psychedelic-assisted therapy.

Nat Hum Behav February 24, 2025 Ginger E. Nicol, Danielle R Adams, Eric J Lenze et al. 4 citations

Psychedelic-assisted therapy (PAT) combines medication with psychotherapy, but many questions remain about how it works, for whom, and in what context. To avoid the typical 17-year delay between research and clinical practice, implementation science can help by simultaneously studying safety, effectiveness, and real-world delivery. Methods like sequential multiple assignment randomized trials (SMART), hybrid study designs, and fidelity measurement can speed implementation while maintaining quality and safety. Substantial changes to regulations, training, and access are needed to accommodate this multimodal therapy outside research settings. The authors advocate proceeding with accelerated caution.

Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.

The Journal of Clinical Psychiatry February 5, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 3 citations

Practitioners who oversee psychedelic therapy sessions slightly prefer an 'emotive' approach—one that emphasizes human and spiritual elements—over a 'neuromodulatory' approach that focuses on biological drug effects. A survey of 40 qualified respondents from at least 4 countries, 11 U.S. states, and 16 institutions found no consensus on many psychological support strategies. Four key themes emerged: the importance of trust, the role of spirituality, creating an emotional setting, and conceptualizing negative experiences. Practitioners trained at the Multidisciplinary Association for Psychedelic Studies or the California Institute of Integral Studies showed a significantly stronger emotive preference than those trained elsewhere.

Provider perspectives on challenges in treatment during psychedelic therapy.

Psychopharmacology October 27, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.

Providers administering psychedelic drugs in clinical trials report a range of challenges, including intense dysphoria during sessions (42% of respondents), disappointment with the intervention (25%), and re-engaging with traumatic experiences (17%). An anonymous survey of 40 qualified respondents who oversaw 1656 psychedelic sessions identified 11 distinct themes of challenges. 70% of respondents felt that individuals with PTSD or prior trauma need additional psychological support, and they recommended an average of 9.8 hours of total psychological support for first-time recipients with serious mental illness. These findings highlight the need to incorporate potential adverse experiences into psychological support protocols for clinical trials and future guidelines.

Brain resting state functional connectivity changes with aerobic exercise, and mindfulness: A narrative review.

Sports Medicine and Health Science July 1, 2026 David Wing, Bart Roelands, Abraham Z. Snyder et al.

A narrative review of 30 studies examined how exercise, mindful movement, and mindfulness training affect resting state functional connectivity (rsFC) in the brains of non-clinical adults. Most studies reported changes in rsFC within the default mode, executive control, and salience networks. However, the largest and most methodologically rigorous study found minimal associations between rsFC and either exercise or mindfulness. Given the inconsistent results, caution is warranted in interpreting changes in rsFC attributable to these interventions. Methodological consistency in fMRI acquisition, data preparation, and analytical approaches is crucial to improve reproducibility and allow for comparison and aggregation.